Drug intelligence / Profile preview

MBF-251

Development stage: Discontinued
Lead developer: Medibiofarma
Modality: Small Molecules

Overview

**MBF-251** is a Medibiofarma small-molecule development candidate designed as a dual antagonist of prostaglandin E2 receptors EP2 and EP4. It was nominated in 2019 for cancer treatment and was expected to enter IND-enabling studies. Medibiofarma subsequently reported that MBF-362 is a salt form of the prior MBF-251 development candidate; MBF-251 itself is reported as discontinued after preclinical development. ([medibiofarma.com](https://medibiofarma.com/medibiofarma-announced-the-nomination-of-a-second-development-candidate/))

Targets

PTGER4 (Prostaglandin E2 receptor EP4 subtype)PTGER2 (Prostaglandin E2 receptor EP2)

Beyond the preview

Go deeper on MBF-251.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBF-251.

Explore the full profile